- Home
- DRH vs HRMY Comparison
DRH vs HRMY Comparison
Compare DRH & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRH
- HRMY
- Stock Information
- Founded
- DRH 2004
- HRMY 2017
- Country
- DRH United States
- HRMY United States
- Employees
- DRH N/A
- HRMY N/A
- Industry
- DRH Real Estate Investment Trusts
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- DRH Real Estate
- HRMY Health Care
- Exchange
- DRH Nasdaq
- HRMY Nasdaq
- Market Cap
- DRH 1.7B
- HRMY 1.9B
- IPO Year
- DRH 2005
- HRMY 2020
- Fundamental
- Price
- DRH $7.77
- HRMY $26.87
- Analyst Decision
- DRH Hold
- HRMY Strong Buy
- Analyst Count
- DRH 6
- HRMY 10
- Target Price
- DRH $8.63
- HRMY $51.30
- AVG Volume (30 Days)
- DRH 3.0M
- HRMY 1.0M
- Earning Date
- DRH 11-06-2025
- HRMY 10-28-2025
- Dividend Yield
- DRH 4.11%
- HRMY N/A
- EPS Growth
- DRH N/A
- HRMY 58.41
- EPS
- DRH 0.28
- HRMY 3.10
- Revenue
- DRH $1,124,753,000.00
- HRMY $772,527,000.00
- Revenue This Year
- DRH N/A
- HRMY $19.94
- Revenue Next Year
- DRH $2.31
- HRMY $16.65
- P/E Ratio
- DRH $27.94
- HRMY $8.72
- Revenue Growth
- DRH 1.72
- HRMY 17.74
- 52 Week Low
- DRH $6.19
- HRMY $26.26
- 52 Week High
- DRH $10.00
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- DRH 32.82
- HRMY 27.45
- Support Level
- DRH $7.87
- HRMY $26.56
- Resistance Level
- DRH $8.08
- HRMY $27.48
- Average True Range (ATR)
- DRH 0.14
- HRMY 1.01
- MACD
- DRH -0.05
- HRMY -0.25
- Stochastic Oscillator
- DRH 0.00
- HRMY 8.99
About DRH Diamondrock Hospitality Company
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.